Skip to main content

Advertisement

Table 1 Demographic and clinical-pathologic characteristics of study cohorts

From: A multiplex immunoassay for the non-invasive detection of bladder cancer

  Cohort #1 P value* Cohort #2 P value*
Bladder cancera (n = 29) Benignb and healthy controls (n = 33) Bladder cancera (n = 100) Benignb and healthy controls (n = 100)
Median age (range, years) 68 (51, 93) 50 (20, 81) <0.0001 70 (20, 89) 50.5 (18, 81) <0.0001
Male:female ratio 25:4 27:6 0.639 81:18 81:19 0.882
Clinical stage and grade
 Tis high-grade 3 (10.3 %)    4 (4.0 %)   
 Ta low-grade 4 (13.8 %)    17 (17.0 %)   
 Ta high-grade 6 (20.7 %)    11 (11.0 %)   
 T1 low-grade 0 (0 %)    4 (4.0 %)   
 T1 high-grade 3 (10.3 %)    22 (22.0 %)   
 ≥T2 high-grade 13 (44.8 %)    42 (42.0 %)   
  1. * Wilcoxon rank sum test
  2. aPrimary BCa; no patient with a history of BCa
  3. bVoiding symptoms, microscopic hematuria